Chemotherapy

Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients

Tuesday, July 7, 2020 - 2:03pm

"This clinical data suggest ctDNA testing is a highly accurate tool in guiding treatment and supports the advancement of our efforts with Signatera to improve cancer management."

Key Points: 
  • "This clinical data suggest ctDNA testing is a highly accurate tool in guiding treatment and supports the advancement of our efforts with Signatera to improve cancer management."
  • Signatera is a custom-built ctDNA test for treatment monitoring and MRD assessment in patients previously diagnosed with cancer.
  • Signatera's test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.
  • Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.Lancet Onco.

Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

Monday, July 6, 2020 - 12:55pm

The results of the global Phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC.

Key Points: 
  • The results of the global Phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC.
  • The median PFS for patients treated with Trodelvy was 5.6 months (95% CI, 4.3-6.3), compared to 1.7 months (95% CI, 1.5-2.6) for chemotherapy (p
  • Trodelvy also met key secondary endpoints of the study, including overall survival and objective response rate.
  • The international, open-label confirmatory Phase 3 study enrolled more than 500 patients with metastatic triple-negative breast cancer who had received at least two prior therapies for metastatic disease.

The Global Breast Cancer Drugs Market is expected to grow from USD 15,188.90 Million in 2019 to USD 25,364.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.92%

Thursday, July 2, 2020 - 4:10pm

On the basis of Geography, the Breast Cancer Drugs Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.

Key Points: 
  • On the basis of Geography, the Breast Cancer Drugs Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Drugs Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Drugs Market?

Chemotherapy Induced Febrile Neutropenia Market Report 2020 - Insights Into the Clinical Development Scenario, Growth Prospects and Pipeline Landscape - ResearchAndMarkets.com

Thursday, July 2, 2020 - 3:46pm

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Febrile Neutropenia market.

Key Points: 
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Febrile Neutropenia market.
  • A detailed picture of the Chemotherapy Induced Febrile Neutropenia pipeline landscape is provided, which includes the disease overview and Chemotherapy Induced Febrile Neutropenia treatment guidelines.
  • The assessment part of the report embraces in-depth Chemotherapy Induced Febrile Neutropenia commercial assessment and clinical assessment of the Chemotherapy Induced Febrile Neutropenia pipeline products from the pre-clinical developmental phase to the marketed phase.
  • The Chemotherapy Induced Febrile Neutropenia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chemotherapy Induced Febrile Neutropenia across the complete product development cycle, including all clinical and nonclinical stages.

Global Small Molecule Cancer Drug Market to 2026 - Drug Price, Dosage & Clinical Trials Insight - ResearchAndMarkets.com

Thursday, July 2, 2020 - 10:23am

The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years.
  • Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    An important parameter that should be associated with any of the cancer treatment is its specificity.
  • 3.2 Small Molecule Cancer Drug vs. Immunotherapy
    3.3 Small Molecule Cancer Drugs vs.

Global Liver Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Region, Forecast & Opportunities, 2025

Wednesday, July 1, 2020 - 5:30pm

Global liver cancer therapeutics market is expected to grow at a brisk CAGR during the forecast period.

Key Points: 
  • Global liver cancer therapeutics market is expected to grow at a brisk CAGR during the forecast period.
  • According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment.
  • Expensive treatments as well as high cost in research and development might hamper the further growth of liver cancer therapeutics market.
  • The intravenous segment is anticipated to dominate the global liver cancer therapeutics market during the forecast period as it is most preferred route of administration for chemotherapy.

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

Monday, June 29, 2020 - 8:33pm

This marks the first immunotherapy approved for thispatient population as a first-line treatment and which is administered to patients without also giving chemotherapy.

Key Points: 
  • This marks the first immunotherapy approved for thispatient population as a first-line treatment and which is administered to patients without also giving chemotherapy.
  • The frequency of MSI-H varies across tumor types and stages, and approximately 5% of patients with metastatic colorectal cancer have MSI-H or dMMR tumors.
  • "Metastatic colorectal cancer is a serious and life-threatening disease with a poor prognosis.
  • By blocking this pathway, Keytruda may help the body's immune system fight the cancer cells and provide a benefit in patients with MSI-H or dMMR metastatic colorectal cancer.

Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

Monday, June 29, 2020 - 1:30pm

Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

Key Points: 
  • Patients in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.
  • Dr. Aivado explained, Chemotherapy remains a critical cornerstone treatment for millions of cancer patients.
  • We treat healthy cells ahead of chemotherapy to prevent those toxicities, importantly, without interrupting chemotherapys potent onslaught against cancer cells.
  • There are two parts to the Phase 1b study: (i) dose optimization and (ii) schedule optimization.

The Future of Colorectal Cancer Care is Precision Medicine

Thursday, June 25, 2020 - 7:20pm

WASHINGTON, June 25, 2020 /PRNewswire/ --Doctors and researchers are abuzz about the field of precision medicineas it alters the landscape of cancer care.

Key Points: 
  • WASHINGTON, June 25, 2020 /PRNewswire/ --Doctors and researchers are abuzz about the field of precision medicineas it alters the landscape of cancer care.
  • "Until recently, the standard of care for colorectal cancer was essentially a one-size-fits-all approach, with surgery followed by chemotherapy and possibly radiation," said Michael Sapienza, CEO of the Alliance.
  • "Precision medicine, and biomarker testing specifically, opens the door to personalized treatments that will change outcomes and save lives.
  • The Colorectal Cancer Alliance is a national nonprofit committed to ending colorectal cancer.

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors

Thursday, June 25, 2020 - 12:00pm

Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.

Key Points: 
  • Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.
  • We will investigate clinically NT-I7s potential to augment the already proven anti-tumor activity of pembrolizumab in CPI-responsive tumors.
  • We hope that NT-I7 in combination with KEYTRUDA can improve the lives of cancer patients with various solid tumors.
  • The goal of the Phase 1b portion of the study, which will enroll up to 18 patients, is to establish a recommended dosing regimen.